You are here

Active Anti-HIV Guanosine/Thymidine Oligonucleotides

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI37332-01A1,
Agency Tracking Number: 29101
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
9391 Grogans Mill Road
The Woodlands, TX 77380
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Robert Rando
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

We will develop a new class of oligonucleotides, which fold themselves into ordered structures andmainly of deoxyguanosine and deoxythymidine (GTOs), as therapeutic antiviral agents active against HGTOs as antiviral agents represents the results of a productive investigation into the mechanism bymediate antiviral activity. Experiments described in the following preliminary results section demonguanosine/thymidine compound I100-15, with a phosphodiester (PD) backbone, is able to suppress HIV-1after removal of the drug from the viral infected cell culture is folded into an intramolecular strutranscription; may inhibit critical portions of HIV-1 replication and is not working by blocking virinteraction with the viral v3 loop. The experiments proposed in this Phase I grant application are svalidate the anti-human immunodeficiency virus type 1 (HIV-1) efficacy of 1100-15 by determining thestructure of this molecule and establishing the anti-HIV-1 mechanism of action. A secondary goal ofobtained structural information to rationally design modifications which will increase the anti-HIV-

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government